Duligotuzumab (MEHD7945A), a BsAb targeting EGFR and HER3, showed no clinical benefit in comparison to cetuximab (anti-EGFR mAb) in phase 2 trials in patients with metastatic colorectal cancer or head and neck squamous cell carcinoma [48]. Here, ERBB3 is linked to head and neck squamous cell carcinoma.